227 related articles for article (PubMed ID: 17026874)
21. The interleukin-5 messenger RNA expression in a patient with idiopathic hypereosinophilic syndrome.
Ho KK; Ho AS; Leung RC; Lai CK; Lai KN
Clin Exp Allergy; 1998 Jul; 28(7):889-92. PubMed ID: 9720824
[TBL] [Abstract][Full Text] [Related]
22. Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract.
Simon D; Wardlaw A; Rothenberg ME
J Allergy Clin Immunol; 2010 Jul; 126(1):3-13; quiz 14-5. PubMed ID: 20392477
[TBL] [Abstract][Full Text] [Related]
23. Advances in eosinophilic diseases in 2018.
Klion AD; Rothenberg ME
J Allergy Clin Immunol; 2019 Dec; 144(6):1490-1494. PubMed ID: 31655098
[TBL] [Abstract][Full Text] [Related]
24. Anti-interleukin-5 antibody therapy in asthma and allergies.
Corren J
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):565-70. PubMed ID: 21971335
[TBL] [Abstract][Full Text] [Related]
25. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
26. Mepolizumab in the treatment of severe eosinophilic asthma.
Fainardi V; Pisi G; Chetta A
Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
[TBL] [Abstract][Full Text] [Related]
27. Eosinophilic myeloid disorders.
Noel P
Semin Hematol; 2012 Apr; 49(2):120-7. PubMed ID: 22449622
[TBL] [Abstract][Full Text] [Related]
28. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
29. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders.
Heinisch IV; Bizer C; Volgger W; Simon HU
J Allergy Clin Immunol; 2001 Jul; 108(1):21-8. PubMed ID: 11447378
[TBL] [Abstract][Full Text] [Related]
30. Eosinophil infiltration in the upper gastrointestinal tract of patients with bronchial asthma.
Imaeda H; Yamaoka M; Ohgo H; Yoneno K; Kobayashi T; Noguchi T; Uchida Y; Soma T; Kayano H; Kanazawa M; Nakamoto H; Nagata M
Allergol Int; 2016 Sep; 65 Suppl():S6-S10. PubMed ID: 27118436
[TBL] [Abstract][Full Text] [Related]
31. Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?
Iurlo A; Cattaneo D
Blood Rev; 2023 Mar; 58():101014. PubMed ID: 36153195
[TBL] [Abstract][Full Text] [Related]
32. Targeting interleukin (IL) 5 for asthma and hypereosinophilic diseases.
Stein ML; Munitz A
Recent Pat Inflamm Allergy Drug Discov; 2010 Nov; 4(3):201-9. PubMed ID: 20807192
[TBL] [Abstract][Full Text] [Related]
33. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
[TBL] [Abstract][Full Text] [Related]
34. [EOSINOPHILIC DISORDERS OF GASTROINTESTINAL TRACT].
Budnevsky AV; Shapovalova MM
Eksp Klin Gastroenterol; 2015; (9):70-4. PubMed ID: 26931014
[TBL] [Abstract][Full Text] [Related]
35. Eosinophils in atopic dermatitis.
Leiferman KM
Allergy; 1989; 44 Suppl 9():20-6. PubMed ID: 2683840
[TBL] [Abstract][Full Text] [Related]
36. [New insights into hypereosinophilic syndromes].
Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
[TBL] [Abstract][Full Text] [Related]
37. Anti-IL-5 and hypereosinophilic syndromes.
Sutton SA; Assa'ad AH; Rothenberg ME
Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
[TBL] [Abstract][Full Text] [Related]
38. Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
Yamada Y; Cancelas JA; Rothenberg ME
Int Arch Allergy Immunol; 2009; 149 Suppl 1():102-7. PubMed ID: 19494514
[TBL] [Abstract][Full Text] [Related]
39. Biological Modulators in Eosinophilic Diseases.
Sriaroon P; Ballow M
Clin Rev Allergy Immunol; 2016 Apr; 50(2):252-72. PubMed ID: 25129490
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies.
Odinius TO; Buschhorn L; Wagner C; Hauch RT; Dill V; Dechant M; Buck MC; Shoumariyeh K; Moog P; Schwaab J; Reiter A; Brockow K; Götze K; Bassermann F; Höckendorf U; Branca C; Jost PJ; Jilg S
J Cancer Res Clin Oncol; 2022 Feb; 148(2):331-340. PubMed ID: 34654952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
